| Li-Huei Tsai | |
|---|---|
| Photo placeholder | |
| Affiliations | Massachusetts Institute of Technology; Howard Hughes Medical Institute |
| Country | United States |
| Research Focus | Alzheimer's Disease, cortical circuit biology, translational neurotechnology |
| Mechanisms | epigenetic regulation, CDK5 signaling, immune and glial biology, brain clearance pathways |
Li Huei Tsai is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Li-Huei Tsai is a Taiwanese American neuroscientist and physician-scientist whose work has shaped modern molecular models of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, especially in [epigenetic regulation], neuronal stress responses, and systems-level neuromodulation.[1][2][3] At MIT, she has led programs that connect basic mechanism discovery to translational intervention design, including non-invasive [gamma-frequency] sensory stimulation approaches and human multicellular disease modeling.[4][5][6][7]
Tsai's research trajectory spans three linked domains. First, her laboratory helped define pathological [CDK5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5--TEMP--/entities)--FIX--/p25 signaling as a driver of neurotoxicity and synaptic dysfunction in degenerative contexts.[2][3] Second, her group established key epigenetic and chromatin-control principles relevant to memory, neuronal resilience, and disease progression.[1][8] Third, more recent work integrates [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--, not just single markers.[1][7][9]
2. Combination interventions: the coexistence of neuronal, glial, and vascular pathology in her recent models argues for multimodal therapeutic design rather than monotherapy assumptions.[6][10]
3. Translational neurotechnology: sensory entrainment studies provide a testable translational bridge between circuit physiology and clinical outcomes, with ongoing refinement of dosage, timing, and responder phenotypes.[4][5]
Her program also intersects with the broader [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- and [protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX-- fields, where disease-modifying benefit likely depends on coordinated effects across cell populations and temporal disease stages.[4][6][10]
Recent publications involving [Li-Huei Tsai[/researchers/[li-huei-tsai[/researchers/[li-huei-tsai[/researchers/[li-huei-tsai--TEMP--/researchers)--FIX-- connect [APOE[/entities/[apoe[/entities/[apoe[/entities/[apoe--TEMP--/entities)--FIX-- biology, [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- neurovascular dysfunction, and translational neuromodulation studies.
Dr. Tsai has trained numerous researchers in the field of neurodegenerative diseases. His/her laboratory has hosted postdoctoral fellows, graduate students, and visiting scientists from around the world.
Future research directions include:
Dr. Tsai maintains collaborations with:
The study of Li Huei Tsai has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.